TXG vs. DHR

Last updated Apr 2, 2026

Compare and contrast key facts about 10x Genomics, Inc. (TXG) and Danaher Corporation (DHR).

Performance

TXG vs. DHR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in 10x Genomics, Inc. (TXG) and Danaher Corporation (DHR). The values are adjusted to include any dividend payments, if applicable.

TXG vs. DHR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
TXG 10x Genomics, Inc.	35.19%	13.58%	-74.34%	53.57%	-75.54%	5.20%	85.70%	44.55%
DHR Danaher Corporation	-16.48%	0.35%	-0.35%	-1.22%	-19.02%	48.57%	45.34%	8.53%

Fundamentals

Market Cap TXG : $2.80B DHR : $135.65B
EPS TXG : -$0.35 DHR : $5.06
PS Ratio TXG : 4.31 DHR : 5.55
PB Ratio TXG : 3.52 DHR : 2.58
Total Revenue (TTM) TXG : $642.82M DHR : $24.57B
Gross Profit (TTM) TXG : $443.88M DHR : $14.97B
EBITDA (TTM) TXG : -$12.53M DHR : $7.02B

Returns By Period

In the year-to-date period, TXG achieves a 35.19% return, which is significantly higher than DHR's -16.48% return.

TXG

• 1D: 3.86%
• 1M: -4.71%
• YTD: 35.19%
• 6M: 77.97%
• 1Y: 154.33%
• 3Y*: -26.61%
• 5Y*: -34.71%
• 10Y*: —

DHR

• 1D: 0.63%
• 1M: -7.19%
• YTD: -16.48%
• 6M: -10.06%
• 1Y: -4.13%
• 3Y*: -4.61%
• 5Y*: -0.43%
• 10Y*: 12.07%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TXG vs. DHR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TXG

TXG Risk / Return Rank: 90
TXG Sharpe Ratio Rank: 91
TXG Sortino Ratio Rank: 89
TXG Omega Ratio Rank: 84
TXG Calmar Ratio Rank: 93
TXG Martin Ratio Rank: 91

DHR

DHR Risk / Return Rank: 31
DHR Sharpe Ratio Rank: 34
DHR Sortino Ratio Rank: 30
DHR Omega Ratio Rank: 30
DHR Calmar Ratio Rank: 33
DHR Martin Ratio Rank: 28

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TXG vs. DHR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and Danaher Corporation (DHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TXG	DHR	Difference
Sharpe ratio Return per unit of total volatility	2.18	-0.13	+2.31
Sortino ratio Return per unit of downside risk	2.83	0.04	+2.79
Omega ratio Gain probability vs. loss probability	1.33	1.01	+0.32
Calmar ratio Return relative to maximum drawdown	5.02	-0.25	+5.27
Martin ratio Return relative to average drawdown	12.15	-0.75	+12.89
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TXG vs. DHR - Sharpe Ratio Comparison

The current TXG Sharpe Ratio is 2.18, which is higher than the DHR Sharpe Ratio of -0.13. The chart below compares the historical Sharpe Ratios of TXG and DHR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TXG	DHR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.18	-0.13	+2.31
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.51	-0.02	-0.49
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.48	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.19	0.66	-0.84

Correlation

The correlation between TXG and DHR is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

TXG vs. DHR - Dividend Comparison

TXG has not paid dividends to shareholders, while DHR's dividend yield for the trailing twelve months is around 0.71%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
TXG 10x Genomics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DHR Danaher Corporation	0.71%	0.56%	0.47%	12.64%	0.38%	0.26%	0.32%	0.44%	0.62%	0.60%	32.55%	0.58%

Drawdowns

TXG vs. DHR - Drawdown Comparison

The maximum TXG drawdown since its inception was -96.47%, which is greater than DHR's maximum drawdown of -45.80%. Use the drawdown chart below to compare losses from any high point for TXG and DHR.

Drawdown Indicators

	TXG	DHR	Difference
Max Drawdown Largest peak-to-trough decline	-96.47%	-45.80%	-50.67%
Max Drawdown (1Y) Largest decline over 1 year	-28.03%	-24.85%	-3.18%
Max Drawdown (5Y) Largest decline over 5 years	-96.47%	-39.81%	-56.66%
Max Drawdown (10Y) Largest decline over 10 years	—	-39.81%	—
Current Drawdown Current decline from peak	-89.10%	-33.79%	-55.31%
Average Drawdown Average peak-to-trough decline	-58.87%	-10.09%	-48.78%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.58%	8.44%	+3.14%

Volatility

TXG vs. DHR - Volatility Comparison

10x Genomics, Inc. (TXG) has a higher volatility of 22.88% compared to Danaher Corporation (DHR) at 8.96%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than DHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TXG	DHR	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.88%	8.96%	+13.92%
Volatility (6M) Calculated over the trailing 6-month period	51.31%	19.14%	+32.17%
Volatility (1Y) Calculated over the trailing 1-year period	71.72%	32.46%	+39.26%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	68.48%	27.75%	+40.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	66.81%	25.24%	+41.57%

Financials

TXG vs. DHR - Profitability Comparison

The chart below illustrates the profitability comparison between 10x Genomics, Inc. and Danaher Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

TXG - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, 10x Genomics, Inc. reported a gross profit of 113.05M and revenue of 166.03M. Therefore, the gross margin over that period was 68.1%.

DHR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Danaher Corporation reported a gross profit of 3.97B and revenue of 6.84B. Therefore, the gross margin over that period was 58.0%.

TXG - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, 10x Genomics, Inc. reported an operating income of -19.54M and revenue of 166.03M, resulting in an operating margin of -11.8%.

DHR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Danaher Corporation reported an operating income of 1.50B and revenue of 6.84B, resulting in an operating margin of 22.0%.

TXG - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, 10x Genomics, Inc. reported a net income of -16.25M and revenue of 166.03M, resulting in a net margin of -9.8%.

DHR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Danaher Corporation reported a net income of 1.20B and revenue of 6.84B, resulting in a net margin of 17.5%.